A detailed history of Lion Street Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lion Street Advisors, LLC holds 570 shares of VRTX stock, worth $232,662. This represents 0.09% of its overall portfolio holdings.

Number of Shares
570
Previous 501 13.77%
Holding current value
$232,662
Previous $234,000 13.25%
% of portfolio
0.09%
Previous 0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$460.0 - $505.78 $31,740 - $34,898
69 Added 13.77%
570 $265,000
Q2 2024

Jul 12, 2024

SELL
$392.81 - $485.53 $49,886 - $61,662
-127 Reduced 20.22%
501 $234,000
Q4 2023

Jan 09, 2024

SELL
$343.0 - $410.68 $1,372 - $1,642
-4 Reduced 0.63%
628 $255,000
Q3 2023

Oct 19, 2023

SELL
$338.18 - $362.46 $292,525 - $313,527
-865 Reduced 57.78%
632 $219,000
Q2 2023

Jul 28, 2023

BUY
$314.42 - $351.91 $260,654 - $291,733
829 Added 124.1%
1,497 $526,000
Q1 2023

Apr 12, 2023

SELL
$283.23 - $323.1 $216,387 - $246,848
-764 Reduced 53.35%
668 $210,000
Q4 2022

Jan 19, 2023

BUY
$285.76 - $321.48 $409,208 - $460,359
1,432 New
1,432 $0
Q2 2022

Jul 19, 2022

BUY
$234.96 - $292.55 $36,888 - $45,930
157 Added 12.31%
1,432 $263,000
Q1 2022

May 10, 2022

SELL
$221.42 - $260.97 $41,848 - $49,323
-189 Reduced 12.91%
1,275 $332,000
Q4 2021

Jan 20, 2022

BUY
$177.01 - $223.45 $5,664 - $7,150
32 Added 2.23%
1,464 $322,000
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $259,750 - $290,681
1,432 New
1,432 $261,000
Q2 2020

Jul 20, 2020

SELL
$225.48 - $295.8 $3,382 - $4,437
-15 Closed
0 $0
Q1 2020

May 06, 2020

BUY
$199.77 - $247.81 $2,996 - $3,717
15 New
15 $4,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Lion Street Advisors, LLC Portfolio

Follow Lion Street Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Street Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lion Street Advisors, LLC with notifications on news.